{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-006985","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2022-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.245879+00:00","generated_at":"2026-06-26T19:36:17.502213+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ChromaDex provides 2022 outlook: net sales +15-20% YoY; Tru Niagen revenue $56.7M in 2021","bullets":["2021 net sales $67.4M (+14% YoY); Tru Niagen sales $56.7M; gross margin 61.5%.","2022 guidance: net sales +15-20% YoY; gross margin ~60%; R&D spend up ~$2M; G&A down $5-6M.","E-commerce 62% of sales; partnerships expanded with Walmart US and Watsons; new SinoPharm partnership for China.","Cash $28.2M, zero debt; adjusted EBITDA excl. legal loss $(2.5)M in 2021; litigation expense largely behind.","Pipeline includes next-gen NAD precursors (NRH, NAR) with 10+ granted patents; 20+ clinical studies supporting NAD+ boosting."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-006985","json":"https://secwatch.observer/filing/0001628280-22-006985.json","markdown":"https://secwatch.observer/filing/0001628280-22-006985.md","text":"https://secwatch.observer/filing/0001628280-22-006985.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000162828022006985/0001628280-22-006985-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000162828022006985/cdxc-20220323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T19:36:17.502213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}